(Q57585515)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

CYP450 genotype and pharmacogenetic association studies: a critical appraisal (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Adrián Llerena

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Julia C Stingl

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Rashmi R Shah

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Andrea Gaedigk

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Michel Eichelbaum

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Robert L Smith

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

18 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

259-275

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

Electronic medical records as a tool in clinical pharmacology: opportunities and challenges

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

A pharmacogenetic versus a clinical algorithm for warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

A randomized trial of genotype-guided dosing of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Complexities of CYP2D6 gene analysis and interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Hepatic Cyp2d and Cyp26a1 mRNAs and activities are increased during mouse pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Genetic polymorphism of hepatocyte nuclear factor-4alpha influences human cytochrome P450 2D6 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4α expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

CYP2D6 phenotype prediction from genotype: which system is the best?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Cytochrome P450 pharmacogenetics in African populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Addressing phenoconversion: the Achilles' heel of personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Inhibition of CYP2D6 activity by bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Potent Inhibition of Cytochrome P450IID6 (Debrisoquin 4-Hydroxylase) by Flecainide In Vitro and In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Sparteine oxidation is practically abolished in quinidine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Investigation of terbinafine as a CYP2D6 inhibitor in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

A CYP2D6 Phenotype-Genotype Mismatch in Japanese Psychiatric Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Variability in drug metabolizing enzyme activity in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Tamoxifen and CYP2D6: a contradiction of data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

The impact of interacting drugs on dispensed doses of warfarin in the Swedish population: A novel use of population based drug registers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Regulation of cytochromes P450 during inflammation and infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Cytochrome P450 regulation and drug biotransformation during inflammation and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Immunological response as a source to variability in drug metabolism and transport

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Inflammation is associated with voriconazole trough concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Cellular injury and neuroinflammation in children with chronic intractable epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

21 January 2018

Cytokines and epilepsy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Resection of the epileptogenic lesion abolishes seizures and reduces inflammatory cytokines of patients with temporal lobe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Pregnancy and pharmacogenomics in the context of drug metabolism and response.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Genetic transmission of cytochrome P450 2D6 (CYP2D6) ultrarapid metabolism: implications for breastfeeding women taking codeine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

CYP2D6 phenotype-specific codeine population pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Pharmacokinetic Interaction of Fluvoxamine and Thioridazine in Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Pharmacogenetics: the therapeutic drug monitoring of the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.172

21 January 2018

Identifiers

DOI

10.2217/PGS.15.172

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26780308%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference